A Phase 1 trial at Children’s Hospital Colorado is evaluating a novel CAR T-cell therapy targeting both CD19 and CD22 proteins in relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.